Table 2.
Instrument/questions | All respondents | Age at diagnosis |
Jurisdiction |
Survival phase |
|||||
---|---|---|---|---|---|---|---|---|---|
≤59 | 60–69 | ≥70 | RoI | NI | Short | Long | Very long | ||
Number of respondents | 3348 Proportion (mean) |
799 Proportion (mean) |
1631 Proportion (mean) |
918 Proportion (mean) |
2338 Proportion (mean) |
1010 Proportion (mean) |
1614 Proportion (mean) |
1075 Proportion (mean) |
659 Proportion (mean) |
Decisional Regret Scale | 0.23 (1.29) | 0.16 (0.87) | 0.23 (1.31) | 0.29 (1.62) | 0.30 (1.50) | 0.13 (0.79) | 0.22 (1.20) | 0.24 (1.33) | 0.24 (1.43) |
p<0.001 | p<0.001 | p=0.012 | |||||||
EORTC QLQ-C30 | 0.08 (1.69) | 0.04 (1.04) | 0.08 (1.61) | 0.15 (2.41) | 0.10 (1.94) | 0.05 (1.13) | 0.08 (1.44) | 0.09 (1.77) | 0.10 (2.17) |
p<0.001 | p<0.001 | p=0.022 | |||||||
EuroQoL EQ-5D-5L | 0.07 (0.22) | 0.04 (0.12) | 0.07 (0.21) | 0.10 (0.33) | 0.09 (0.27) | 0.04 (0.11) | 0.05 (0.17) | 0.09 (0.25) | 0.10 (0.29) |
p<0.001 | p<0.001 | p=0.010 | |||||||
EORTC QLQ-PR25 | 0.31 (2.94) | 0.24 (2.15) | 0.30 (2.87) | 0.41 (3.76) | 0.31 (2.96) | 0.32 (2.89) | 0.29 (2.54) | 0.32 (3.07) | 0.37 (3.72) |
p<0.001 | p=0.713 | p<0.001 | |||||||
DASS-21 | 0.17 (1.81) | 0.13 (1.13) | 0.15 (1.71) | 0.24 (2.60) | 0.20 (2.24) | 0.10 (0.83) | 0.15 (1.54) | 0.18 (1.87) | 0.20 (2.39) |
p<0.001 | p<0.001 | p=0.004 | |||||||
Survey-specific questions | |||||||||
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Treatment received | 93 (3%) | 14 (2%) | 40 (2%) | 39 (4%) | 72 (3%) | 21 (2%) | 34 (2%) | 31 (3%) | 28 (4%) |
p=0.004 | p=0.106 | p=0.018 | |||||||
Adverse effects | 87 (3%) | 10 (1%) | 46 (3%) | 31 (3%) | 63 (3%) | 24 (2%) | 51 (3%) | 22 (2%) | 14 (2%) |
p=0.016 | p=0.595 | p=0.143 |
Survivorship phase: short-term, long-term and very long-term refer to survivors <5, 5–9.9 and ≥10 years postdiagnosis, respectively.
ANOVA, analysis of variance; DASS, 21-question Depression, Anxiety and Stress Scale; NI, Northern Ireland; RoI, Republic of Ireland.